Ideal for sample volumes of 1-100 L! We introduce products that support large-capacity ultrafiltration with TFF!
Exosome purification utilizes various ultracentrifugation methods with established size fractionation protocols. However, due to the nature of ultracentrifugation, there is a challenge in increasing the amount of sample that can be processed. Cytiva offers a "TFF system" that combines flow systems and tangential flow filtration, which is introduced as one solution to this challenge. Additionally, there are examples of its use for the purification and concentration of exosomes from cultured cells. To perform exosome purification from large-volume samples derived from cultured cell lines, we provide products suitable for each step, including the removal of cells and debris, the removal of microvesicles and other cellular vesicles, and the purification of exosomes. 1. Debris removal from cell culture media: Supracap 50, 100 depth filter capsules 2. Removal of microvesicles and other cellular vesicles: VacuCap bottle-top filters 3. Exosome purification: Minimate EVO TFF system [1] Jong et al., Nat Commun. 2020. 11. 1113.
Inquire About This Product
basic information
【Workflow for Large-Volume (100 mL or more) Exosome Purification】 ■(1) Removal of Cells and Debris ・Collect culture supernatant ・Clarify using depth filter without centrifugation ■(2) Removal of Microvesicles ・Filter using bottle top filter or capsule filter ・Use 0.1 or 0.2 μm diameter ■(3) Purification of Exosomes ・Purify using TFF (Tangential Flow Filtration) *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Purpose】 ■Streamlining the exosome purification workflow *For more details, please refer to the PDF document or feel free to contact us.*
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
